# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst John Newman maintains 2seventy bio (NASDAQ:TSVT) with a Buy and lowers the price target from $12 t...
2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 2...
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...
Citigroup analyst Samantha Semenkow maintains 2seventy bio (NASDAQ:TSVT) with a Buy and raises the price target from $9 to $12.
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior ...
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in r...
Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunop...